Pediatric Hepatic Tumors (HEPATOBIO)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04274868 |
Recruitment Status :
Recruiting
First Posted : February 18, 2020
Last Update Posted : February 18, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Liver Tumor |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 600 participants |
Observational Model: | Cohort |
Time Perspective: | Other |
Target Follow-Up Duration: | 10 Years |
Official Title: | Constitution of a Centralized Biological Resources Collection and Associated With a Clinical Database for Childhood Liver Tumors Diagnosed in France (Retrospective Collection From 1990 and Prospective) |
Actual Study Start Date : | September 10, 2015 |
Estimated Primary Completion Date : | September 2025 |
Estimated Study Completion Date : | September 2025 |
Group/Cohort |
---|
Children and adolescents with liver tumor
Patients treated after 01/01/1990 for a primary liver tumor before the age of 18.
|
- Establish a national bank of rare biological material [ Time Frame: Up to 10 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
-
- For inclusion in the clinical database:
- Children and adolescents (≤18 years at diagnosis) suffering from a primary liver tumor diagnosed after 01/01/1990 and treated in France
- Informed consent to the computerization of data signed by the patient or by parents or legal representatives if he is a minor.
-
- For inclusion in the biological collection (CRB Paris Sud):
- Additional criteria:
- Availability of biological samples (tumor tissue, healthy tissue, plasma and / or serum).
- Informed consent to the use of biological remains signed by the patient or by parents or legal representatives if he is a minor.
-
- For the inclusion of deceased patients:
- Obtaining consent or failing this, seeking non-opposition to the computerization of data (for inclusion in the database) and the use of biological remains (for inclusion in the biological collection) of the patient or both parents or the legal guardian if he is a minor.
Exclusion Criteria:
- None
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04274868
Contact: Brenda Mallon | 0142114211 ext +33 | branda.mallon@gustaveroussy.fr |
France | |
Gustave Roussy | Recruiting |
Villejuif, Val De Marne, France, 94800 | |
Contact: Branda Mallon 0142114211 ext +33 branda.mallon@gustaveroussy.fr |
Responsible Party: | Gustave Roussy, Cancer Campus, Grand Paris |
ClinicalTrials.gov Identifier: | NCT04274868 |
Other Study ID Numbers: |
2015-A00180-49 |
First Posted: | February 18, 2020 Key Record Dates |
Last Update Posted: | February 18, 2020 |
Last Verified: | February 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Liver Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Liver Diseases |